Corbus Pharmaceuticals Holdings, Inc. CRBP

CRBP Company Overview

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision oncology and immunology therapies. The company operates primarily within the biotechnology and pharmaceutical industries, with a strategic emphasis on oncology drug discovery and development. Corbus’ core business is centered on advancing internally developed therapeutic candidates targeting solid tumors and immune-mediated diseases, with revenue generation currently tied primarily to financing activities and collaboration arrangements rather than commercialized product sales, as the company does not yet market approved therapies.

Historically, Corbus was known for developing cannabinoid-based therapies targeting inflammatory and fibrotic diseases, including systemic sclerosis and cystic fibrosis-related conditions. The company later shifted its strategic direction toward oncology through licensing transactions and pipeline restructuring. Corbus has increasingly focused on next-generation antibody-drug conjugates and precision medicine platforms, positioning itself as a small-cap biotechnology company pursuing differentiated therapeutic mechanisms in areas with high unmet medical need.